| SEGMENT INFORMATION |
NOTE 8 – SEGMENT INFORMATION | a. | The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results on a consolidated basis based on net income (losses). |
| | | | | | | | | | | | | | | Six Months Ended June 30, | | Three Months Ended June 30, | (U.S. dollars in thousands) | | 2026 | | 2025 | | 2026 | | 2025 | Revenues from customers | | $ | 53,646 | | $ | 25,771 | | $ | 19,896 | | $ | 15,658 | Less: | | | | | | | | | | | | | Employee salaries and related expenses | | | 14,352 | | | 10,649 | | | 7,655 | | | 5,444 | Sub-contractors expense | | | 8,340 | | | 7,463 | | | 3,899 | | | 4,773 | Interest expense | | | - | | | - | | | - | | | - | Interest income | | | (848) | | | (528) | | | (660) | | | (272) | Depreciation | | | 810 | | | 706 | | | 406 | | | 360 | R&D grant | | | (2,100) | | | | | | (2,100) | | | | Other segment expenses, net* | | | 7,091 | | | 10,552 | | | 5,836 | | | 4,692 | Income (loss) before taxes on income | | | 26,001 | | | (3,071) | | | 4,860 | | | 661 | Taxes on income | | | 3,907 | | | 384 | | | 1,083 | | | 497 | Segment net income (loss) | | $ | 22,094 | | $ | (3,455) | | $ | 3,777 | | $ | 164 |
* Other expenses included in net income include raw materials, rent, and utilities, and others. | c. | The following table summarizes the Company’s disaggregation of revenues: |
| | | | | | | | | | | | | | Six Months Ended June 30, | | Three Months Ended June 30, | | (U.S. dollars in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | Gaucher disease: | | | | | | | | | | | | | Pfizer (Ireland) | $ | 5,731 | | $ | 12,626 | | $ | 4,279 | | $ | 5,647 | | Fiocruz (Brazil) | $ | 3,968 | | $ | 3,016 | | $ | 1,514 | | $ | - | | Fabry disease: | | | | | | | | | | | | | Chiesi (Italy) | $ | 17,548 | | $ | 9,793 | | $ | 14,035 | | $ | 9,793 | | Total revenues from selling goods | $ | 27,247 | | $ | 25,435 | | $ | 19,828 | | $ | 15,440 | | Revenues from license and R&D services | $ | 26,399 | | $ | 336 | | $ | 68 | | $ | 218 | |
| d. | Long lived assets are located in Israel. |
|